PepGen is a clinical-stage company developing PGN-EDODM1, a peptide-delivered oligonucleotide for myotonic dystrophy type 1, a muscle disease with no approved treatment; it is not approved.
PepGen's case rests on PGN-EDODM1, a peptide-delivered oligonucleotide whose splicing correction rose with dose to 53.7% after a single dose in Phase 1. In the multiple-dose Phase 2 FREEDOM2, the 5 mg/kg cohort showed 7.3% splicing correction versus 6.8% on placebo, with no change in walking or grip strength. Data from 10 mg/kg come in November 2026 and from 12.5 mg/kg in 1H 2027. FDA's partial hold on the U.S. part has no reported resolution, and cash should last into Q4 2027.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FREEDOM2 10 mg/kg data show clear splicing correction
Does repeat dosing at 10 mg/kg correct splicing clearly more than placebo, with signs of better muscle function?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
PepGen's PGN-EDODM1 moves to its highest FREEDOM2 dose after a safety review; 10 mg/kg data in November follow a 5 mg/kg cohort that barely separated from placebo, and the U.S. trial remains on partial hold
PGN-EDODM1's Phase 2 dose-escalation data will determine whether best-in-class splicing correction translates to clinical benefit in DM1 patients
FREEDOM-DM1 15 mg/kg cohort: 53.7% mean splicing correction
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neuromuscular diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
9 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.